The IBD mar­ket is set to soar to $32B. Ab­b­Vie could be the big win­ner, but there's meat left on the bone — top an­a­lyst

Ab­b­Vie has pinned much of its hopes in a post-Al­ler­gan merg­er fu­ture on re­cent im­munol­o­gy launch­es Skyrizi and Rin­voq, which are ex­pect­ed to off­set the sales of a biosim­i­lar Hu­mi­ra. To get there, both drugs will need big sales, and a boom in the rapid­ly grow­ing IBD mar­ket could be just the tick­et, one an­a­lyst writes.

The IBD mar­ket, which cov­ers Crohn’s dis­ease and ul­cer­a­tive col­i­tis, could be worth up to $32 bil­lion in sales per year by 2025, near­ly dou­bling its cur­rent val­ue of around $18 bil­lion, SVB Leerink an­a­lyst Ge­of­frey Porges wrote in a note to clients Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER